ストックスクリーナーアプリを入手
4.69
3.30%
-0.16
アフターアワーズ：
4.69
前日終値:
$4.85
開ける：
$5
24時間の取引高:
18,898
Relative Volume:
0.04
時価総額：
$5.30M
収益：
-
当期純損益:
$-36.46M
株価収益率:
-1.9542
EPS:
-2.4
ネットキャッシュフロー:
$-30.20M
1週間 パフォーマンス:
-4.48%
1か月 パフォーマンス:
+90.65%
6か月 パフォーマンス:
+146.19%
1年 パフォーマンス:
-27.96%
1日の値動き範囲:
$4.38
$5.00
1週間の範囲:
$4.255
$5.4837
52週間の値動き範囲:
$1.3137
$6.992
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
TCRT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
4.69 | 5.30M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
Alaunos Therapeutics Inc (TCRT) 最新ニュース
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies - The Manila Times
PMGC Capital Urges Alaunos Therapeutics to Accept Strategic Financing Opportunity - Nasdaq
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) - GlobeNewswire
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading - Bluefield Daily Telegraph
Clean Financing Deal: Top Wall Street Bank Backs Alaunos While Major Investor PMGC Capital Demands Action - Stock Titan
Alaunos Therapeutics Amends Warrant Agreement with Mast Hill - TipRanks
Alaunos Therapeutics Secures $25M Equity Purchase Deal - MSN
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update - Defense World
Ziopharm: Q1 Earnings Snapshot - CT Insider
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 2.4% – Time to Sell? - Defense World
PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics - TipRanks
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World
Alaunos Therapeutics announces board member resignation - Investing.com Australia
Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada
Form 8-KCurrent report - ADVFN
Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks
Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada
Alaunos Therapeutics announces private placement of preferred stock - Investing.com
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAllakos (NASDAQ:ALLK), Alumis (NASDAQ:ALMS) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alaunos Therapeutics Inc. (TCRT) reports earnings - Quartz
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics, Inc. SEC 10-Q Report - TradingView
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
ELABPMGC Holdings Latest Stock News & Market Updates - Stock Titan
Alaunos Therapeutics Inc (TCRT) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.42%
大文字化:
|
ボリューム (24 時間):